Status: Information only — we are not accepting new claims for this lawsuit. Federal Zantac claims were dismissed and are on appeal, settlements are closed to new claimants, and a Delaware court dismissed about 80,000 cases in April 2026.

Zantac Lawsuit
The FDA recalled all Zantac products in April 2020 due to dangerous NDMA contamination.
See Claim StatusATTENTION: ZANTAC USERS
Zantac (Ranitidine) was found to contain NDMA — a probable human carcinogen. The FDA recalled all Zantac products in April 2020. Studies have linked long-term NDMA exposure to multiple cancers.
Not Accepting New Claims
Claim Status
Federal Zantac claims were dismissed and are on appeal, settlements are closed to new claimants, and a Delaware court dismissed about 80,000 cases in April 2026.
If you already filed a claim, contact the attorney or claims office handling it. You may still qualify for other active lawsuits.
See Active LawsuitsFREE CASE REVIEW
SEE IF YOU MAY QUALIFY
How do we help YOU?
Zantac (Ranitidine) was found to contain NDMA — a probable human carcinogen. The FDA recalled all prescription and OTC Zantac products in April 2020. Studies have linked long-term NDMA exposure to multiple cancers.
How does filing a claim work?
- 1. Tell us what happened. Choose the product and answer a few questions.
- 2. Our intake team reviews your answers.
- 3. If it fits, an independent attorney or their team contacts you to explain your options.
- 4. You decide whether to move forward.
- Remember: the case review is free. Attorneys commonly work on contingency, and fee terms are set by the attorney.
Zantac was found to contain NDMA — a probable human carcinogen — and was recalled by the FDA in April 2020.
NDMA (N-Nitrosodimethylamine) is inherently unstable and can form and increase over time in Ranitidine products, especially at higher temperatures. Long-term exposure to NDMA is alleged to be linked to the development of multiple forms of cancer. Manufacturers are accused of knowing about this contamination risk and failing to warn consumers.
What Is the Zantac Lawsuit?
Zantac (Ranitidine), once one of the world's best-selling heartburn medications, was found to contain dangerous levels of NDMA — a probable human carcinogen. The FDA recalled all prescription and OTC Zantac products in April 2020.
Lawsuits allege manufacturers knew or should have known about NDMA contamination and failed to warn consumers — leaving millions of patients exposed to a cancer-causing substance without any warning.
Who Qualifies for a Zantac Lawsuit?
Individuals who regularly took Zantac or Ranitidine and were subsequently diagnosed with bladder, breast, colon, esophageal, kidney, liver, pancreatic, prostate, or stomach cancer may be eligible to file a claim.
Did Zantac contribute to your cancer diagnosis?
See Claim StatusCancers Alleged to Be Linked to Zantac (NDMA)
- Bladder Cancer
- Breast Cancer
- Colorectal / Colon Cancer
- Esophageal Cancer
- Kidney Cancer
- Liver Cancer
- Pancreatic Cancer
- Prostate Cancer
- Stomach Cancer
What Is NDMA and Why Is It Dangerous?
NDMA (N-Nitrosodimethylamine) is a probable human carcinogen found in Zantac's active ingredient, Ranitidine. The chemical is inherently unstable and can form and increase over time, especially under higher temperatures during storage or shipping.
Long-term exposure to NDMA is alleged to be linked to the development of multiple forms of cancer. Despite this, manufacturers are accused of failing to adequately warn consumers about the risk of NDMA contamination in their products.
Zantac Lawsuit Timeline and Settlements
The FDA issued its recall of Zantac in April 2020. Litigation is ongoing across state and federal courts. Settlement amounts depend on cancer diagnosis type, severity, duration of Zantac use, and other health impacts.
Last reviewed: · Lawsuit descriptions summarize allegations made in court filings, not proven facts.
